Pharma & Biotech Global Week in Review 29 Feb 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Motion to German Parliament: No patentability for agricultural livestock and plants (IPEG)

CAFC affirms decision by BPAI, holding Monsanto was not time-barred under 35 U.S.C. § 135(b)(1) and Monsanto’s application claims entitled to seniority: Pioneer Hi-Bred International. v. Monsanto Technology (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

WHO resolution intended to address global counterfeit drug market (IP Osgoode)

WIPO achieves single legal text on genetic resources; indigenous peoples back (IP Watch)

Introduction to life science collaboration agreements (Richard C. Hsu)

Rare Diseases – are there sufficient incentives to develop treatments? (IPKat)

Canada / EU: CETA hits a snag over patent law changes demanded by large pharmaceutical companies (Michael Geist)

Germany: Motion to German Parliament: No patentability for agricultural livestock and plants (IPEG)

India: Biosimilars – Indian companies getting real? (Apothecurry)

EU: SPCs and the Unified Court Agreement (The SPC Blog)

EU: EPO updates on Monsanto’s virus resistant melon patent (IPKat)

South America: Size matters: PhRMA’s Special 301 picks for South America (KEI)

UK: EWHC (Pat) hands down judgment on affect of Medeva and the reasoned Order on the Queensland SPC applications: Queensland v Comptroller General of Patents (EPLAW)

US: CAFC affirms decision by BPAI, holding Monsanto was not time-barred under 35 U.S.C. § 135(b)(1) and Monsanto’s application claims entitled to seniority: Pioneer Hi-Bred International. v. Monsanto Technology (Patent Docs)

US: Falana v Kent State: Inventorship of chemical compounds (Pharma Patents)

US: Mayo v Prometheus – a critique of oral arguments before the Supreme Court (Spicy IP)

US: Two newly issued meganuclease patents immediately challenged by Cellectis in declaratory judgment action: Cellectis v Precision BioSciences (Holman’s Biotech IP Blog) (Patent Docs)

US: PTO genetic testing study: What’s patents got to do with it (BIOtechNOW)

US: Latest legislative attempt on reverse payment ANDA settlements – Protecting Consumer Access to Generic Drugs Act of 2012 (Patent Docs)

US: FDA discusses initial considerations for Biosimilar Guidance Documents (Patent Docs)

US: Hyman, Phelps & McNamara, P.C. submits supplemental comments to FDA to highlight FDA description of RUO guidance in Par Brief (FDA Law Blog)

US: FDA Denies Washington Legal Foundation Citizen Petition (FDA Law Blog)

US: FDA flexes new enforcement muscle; issues warning letter for failure to meet required postmarketing study milestone dates (FDA Law Blog)

 

Products

Diacerein – France: Civil liability because of the enforcement of a preliminary injunction: Biogaran v Laboratoire Medidom (Kluwer Patent Blog)

Dual Gold Safeneur (Benoxacor and (S)-metolachlor) – France: Cour de Cassation rejection of appeal against the refusal of an SPC – French ruling now available in English too (The SPC Blog)

Taxotere (Docetaxel) – Sweden: Patent invalidation and costs: Hospira v Aventis (EPLAW)

Fusilev (Levoleucovorin) – US: Spectrum Pharmaceuticals files patent infringement suit against InnoPharma in response to Para IV challenge (Patent Docs)

Prandin (Repaglinide) – US: Novo Nordisk files patent infringement complaint against Aurobindo in response to Para IV certification filing (Patent Docs)

Seroquel (Quetiapine fumarate) – US: Hatch-Waxman watch: AstraZeneca Pharmaceutical  v. Intellipharmaceutics Corp. (Patent Docs)

Yasmin (Drospirenone) – US: Is it conceivable (or not) that Hatch-Waxman method patent infringement lawsuits are limited to information in the “indications and usage” drug labeling section? (FDA Law Blog)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,696 other followers

%d bloggers like this: